drugset / Trial / NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Timeline
- Start
- 2021-03-12
- Primary completion
- 2025-10-03
- Completion
- 2027-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teclistamab | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |
| Background | Nirogacestat | Small molecule | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |